Sridhar K. Rabindran

10.6k total citations · 2 hit papers
45 papers, 5.7k citations indexed

About

Sridhar K. Rabindran is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Sridhar K. Rabindran has authored 45 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 19 papers in Oncology and 7 papers in Organic Chemistry. Recurrent topics in Sridhar K. Rabindran's work include Heat shock proteins research (10 papers), Cancer-related Molecular Pathways (8 papers) and HER2/EGFR in Cancer Research (6 papers). Sridhar K. Rabindran is often cited by papers focused on Heat shock proteins research (10 papers), Cancer-related Molecular Pathways (8 papers) and HER2/EGFR in Cancer Research (6 papers). Sridhar K. Rabindran collaborates with scholars based in United States, Canada and Germany. Sridhar K. Rabindran's co-authors include Carl Wu, Joachim Clos, Lee M. Greenberger, Jan Wiśniewski, Allan Wissner, Chi Wu, Gianfranco Giorgi, John P. McGinnis, Raymond I. Haroun and D D Ross and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Sridhar K. Rabindran

44 papers receiving 5.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

2005 774 citations Eunice L. Kwak, Raffaella Sordella et al. Proceedings of the National Academy of Sciences profile →
Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

2004 503 citations Sridhar K. Rabindran, Carolyn Discafani et al. Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sridhar K. Rabindran United States	29	3.5k	2.5k	1.1k	854	506	45	5.7k
Shiro Akinaga Japan	43	3.7k 1.1×	1.8k 0.7×	408 0.4×	470 0.6×	381 0.8×	122	6.6k
Lawrence F. Povirk United States	45	5.7k 1.6×	2.1k 0.8×	265 0.2×	869 1.0×	1.2k 2.4×	111	6.8k
Pier Giorgio Petronini Italy	37	1.9k 0.6×	1.3k 0.5×	1.2k 1.1×	406 0.5×	548 1.1×	117	3.9k
Laura Sepp‐Lorenzino United States	36	3.6k 1.0×	1.0k 0.4×	198 0.2×	732 0.9×	788 1.6×	78	4.9k
Joseph Fargnoli United States	34	2.3k 0.7×	750 0.3×	205 0.2×	277 0.3×	627 1.2×	56	3.9k
Roberta Alfieri Italy	39	2.1k 0.6×	1.5k 0.6×	1.4k 1.3×	403 0.5×	648 1.3×	122	4.1k
John Sensintaffar United States	17	2.0k 0.6×	424 0.2×	473 0.4×	226 0.3×	284 0.6×	29	2.8k
Gabriella Zupi Italy	45	3.9k 1.1×	1.9k 0.8×	431 0.4×	169 0.2×	973 1.9×	161	5.6k
Ajit Bharti United States	35	3.2k 0.9×	957 0.4×	169 0.2×	175 0.2×	343 0.7×	55	4.3k
Angelika M. Burger United States	37	2.7k 0.8×	981 0.4×	273 0.3×	491 0.6×	684 1.4×	81	4.1k

Countries citing papers authored by Sridhar K. Rabindran

Since Specialization

Citations

This map shows the geographic impact of Sridhar K. Rabindran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sridhar K. Rabindran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sridhar K. Rabindran more than expected).

Fields of papers citing papers by Sridhar K. Rabindran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sridhar K. Rabindran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sridhar K. Rabindran. The network helps show where Sridhar K. Rabindran may publish in the future.

Co-authorship network of co-authors of Sridhar K. Rabindran

This figure shows the co-authorship network connecting the top 25 collaborators of Sridhar K. Rabindran. A scholar is included among the top collaborators of Sridhar K. Rabindran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sridhar K. Rabindran. Sridhar K. Rabindran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Borghaei, Hossein, Kenneth J. O’Byrne, Luis Paz‐Ares, et al.. (2023). Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial. ESMO Open. 8(6). 102065–102065. 23 indexed citations

Dumble, Melissa, Ming‐Chih Crouthamel, Shuyun Zhang, et al.. (2014). Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor. PLoS ONE. 9(6). e100880–e100880. 116 indexed citations

Sabbatini, Peter, Jason L. Rowand, Arthur Groy, et al.. (2009). Antitumor Activity of GSK1904529A, a Small-molecule Inhibitor of the Insulin-like Growth Factor-I Receptor Tyrosine Kinase. Clinical Cancer Research. 15(9). 3058–3067. 62 indexed citations

Sabbatini, Peter, Susan Korenchuk, Jason L. Rowand, et al.. (2009). GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Molecular Cancer Therapeutics. 8(10). 2811–2820. 86 indexed citations

Rabindran, Sridhar K., Peter Sabbatini, Susan Korenchuk, et al.. (2009). Abstract #1740: Characterization of GSK1838705A, a small molecule inhibitor of the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase that delays growth of IGF-1R-dependent tumors and causes regression of ALK-dependent tumors in vivo. Cancer Research. 69. 1740–1740. 2 indexed citations

Wang, Yanong D., Biqi Wu, S.A. Johnson, et al.. (2008). Synthesis, SAR study and biological evaluation of novel pyrazolo[1,5-a]pyrimidin-7-yl phenyl amides as anti-proliferative agents. Bioorganic & Medicinal Chemistry. 17(5). 2091–2100. 34 indexed citations

Tsou, Hwei‐Ru, William Hallett, Marvin F. Reich, et al.. (2005). Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity. Journal of Medicinal Chemistry. 48(4). 1107–1131. 246 indexed citations

Kwak, Eunice L., Raffaella Sordella, Daphne W. Bell, et al.. (2005). Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proceedings of the National Academy of Sciences. 102(21). 7665–7670. 774 indexed citations breakdown →

Grillo, Mary, Matthew J. Bott, John P. McGinnis, et al.. (2005). Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression. Breast Cancer Research and Treatment. 95(2). 185–194. 73 indexed citations

10.

Jennings, Lee D., Scott L. Kincaid, Yanong D. Wang, et al.. (2005). Parallel synthesis and biological evaluation of 5,6,7,8-tetrahydrobenzothieno[2,3-d]pyrimidin-4(3H)-one cytotoxic agents selective for p21-deficient cells. Bioorganic & Medicinal Chemistry Letters. 15(21). 4731–4735. 70 indexed citations

11.

Wang, Yanong D., Steven W. Johnson, Dennis Powell, et al.. (2005). Inhibition of tumor cell proliferation by thieno[2,3-d]pyrimidin-4(1H)-one-based analogs. Bioorganic & Medicinal Chemistry Letters. 15(16). 3763–3766. 75 indexed citations

12.

Gopalsamy, Ariamala, Hui Yang, John W. Ellingboe, et al.. (2005). Pyrazolo[1,5-a]pyrimidin-7-yl phenyl amides as novel anti-proliferative agents: parallel synthesis for lead optimization of amide region. Bioorganic & Medicinal Chemistry Letters. 15(6). 1591–1594. 56 indexed citations

13.

Rabindran, Sridhar K.. (2004). Antitumor activity of HER-2 inhibitors. Cancer Letters. 227(1). 9–23. 70 indexed citations

14.

Wissner, Allan, Marvin F. Reich, M. Brawner Floyd, et al.. (2002). Synthesis and Structure−Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2). Journal of Medicinal Chemistry. 46(1). 49–63. 212 indexed citations

15.

Zhang, Nan, Biqi Wu, Allan Wissner, et al.. (2002). 4-Anilino-3-cyanobenzo[g]quinolines as Kinase Inhibitors. Bioorganic & Medicinal Chemistry Letters. 12(3). 423–425. 13 indexed citations

16.

Hoang, Arthur T., Jiapeng Huang, Nandini Rudra-Ganguly, et al.. (2000). A Novel Association between the Human Heat Shock Transcription Factor 1 (HSF1) and Prostate Adenocarcinoma. American Journal Of Pathology. 156(3). 857–864. 124 indexed citations

17.

Rabindran, Sridhar K., H He, Manu Smriti Singh, et al.. (1998). Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C.. PubMed. 58(24). 5850–8. 262 indexed citations

18.

Martínez‐Balbás, Marian A., Anup Dey, Sridhar K. Rabindran, Keiko Ozato, & Carl Wu. (1995). Displacement of sequence-specific transcription factors from mitotic chromatin. Cell. 83(1). 29–38. 380 indexed citations

19.

Rabindran, Sridhar K., et al.. (1994). Interaction between Heat Shock Factor and hsp70 Is Insufficient To Suppress Induction of DNA-Binding Activity In Vivo. Molecular and Cellular Biology. 14(10). 6552–6560. 26 indexed citations

20.

Wu, Carl, Joachim Clos, Raymond I. Haroun, et al.. (1994). 16 Structure and Regulation of Heat Shock Transcription Factor. Cold Spring Harbor Monograph Archive. 26. 395–416. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact